20231130-华安证券-太极集团-600129.SH-核心产品表现稳定_盈利能力持续提升_4页_344kb

Taiji Group (600129) Report Summary

Financial Performance

• 2023 Q1-3 Revenue: 121,830 million CNY, representing a +145.8% year-over-year increase.
• 2023 Q1-3 Net Profit: 75,800 million CNY, showing a significant +19,757% year-over-year growth.
• Q3 2023 revenue declined by -74.3% year-over-year, while Q3 net profit surged +5,186% year-over-year.
• Profitability improved, with gross margin increasing to 48.99% from 45.4% in the previous year, and net profit margin rising from 25% to 63.0%.

Product Highlights

• Core products drove revenue growth, particularly respiratory system drugs (+5,287% YoY for前三季度, mainly due to increased sales of cough syrup) and digestive system drugs (+4,626% YoY).
• Antimicrobial drugs saw strong performance, while some categories like nervous system and anti-cancer drugs had negative growth.
• Overall, income from products like respiratory and digestive drugs contributed significantly.

Strategic Initiatives and Market Position

• The company strengthened its research and innovation efforts, including obtaining six new drug approvals, 13 patent authorizations, and partnerships with 17 universities and research institutions.
• A robust national marketing network, including 20+ commercial enterprises, ensures strong market presence, and resources like 160,000 acres of herbal cultivation support supply chains.

Investment Recommendation

• Maintain "Buy" rating for 2023-2025, with projected revenue growth at 27.2%, 20.6%, and 20.8% for those years, and net profit targets of +1,734%, +40.7%, and +40.3%.
• PE valuations range from 30x to 15x.

Key Risks

• Potential policy changes, corporate governance uncertainties, and sales performance risks for core products.